Giant Gastric Gastrointestinal Stromal Tumor (GIST)

Date

2016

Type:

Artículo

item.page.extent

3

item.page.accessRights

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

Springer

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

item.page.other

item.page.references

Abstract

Gastrointestinal stromal tumors (GIST) represent 0.1–3 % of gastrointestinal malignancy. Surgery is the mainstay of treatment, but in high-risk tumors, imatinib can help to achieve better oncological outcomes. We present a rare case of a patient with gastric GIST with very aggressive evolution in a short period of time despite the use of neoadjuvant therapy with imatinib.

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

J Gastrointest Surg (2017) 21:202-204

Keywords

GIST, Gastric, Imatinib

item.page.dc.rights

item.page.dc.rights.url